JENNIFER ONYEKONWU-MCGILL: Open Payments
NPI 1063686616 · CLAREMONT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,709 in 226 payments from 17 companies in 2025. Trend: 2023 $4,785 · 2024 $4,945 · 2025 $4,709
Food & beverage: $4,592Education: $117
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 52 | $1,174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $502 |
| Otsuka America Pharmaceutical, Inc. | 22 | $455 |
| Alkermes, Inc. | 24 | $450 |
| Janssen Pharmaceuticals, Inc | 20 | $415 |
| Neurocrine BioSciences, Inc. | 14 | $369 |
| E.R. Squibb & Sons, L.L.C. | 13 | $354 |
| ABBVIE INC. | 24 | $338 |
| Axsome Therapeutics, Inc. | 11 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $173 |
Products named: AUSTEDO XR, CAPLYTA, UZEDY, ARISTADA, INVEGA SUSTENNA, INGREZZA, REXULTI, VRAYLAR.
Industry payments across CA — which companies pay providers there.
